Equillium, Inc. (NASDAQ:EQ) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Equillium has a “Moderate Buy” consensus rating from 11 analysts: seven buys, two strong buys, one hold and one sell. The average 12-month price target is $7.57.
• EQ shares opened at $1.68, below their 50-day and 200-day moving averages of $2.21 and $2.34, respectively. The stock has traded between $0.76 and $3.54 over the past year.
• Institutional investors own 27.05% of Equillium, with several firms recently initiating or increasing positions. The clinical-stage biotechnology company is developing itolizumab for severe autoimmune and inflammatory diseases.

Equillium, Inc. (NASDAQ:EQ - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $7.57.

Several brokerages have recently commented on EQ. Roth Capital reissued a "buy" rating and set a $12.00 price target on shares of Equillium in a research note on Friday, September 4th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Equillium in a research report on Monday, September 21st. Zacks Research upgraded Equillium from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 11th. Wall Street Zen lowered shares of Equillium from a "hold" rating to a "sell" rating in a research report on Saturday, September 19th. Finally, Clear Str upgraded shares of Equillium to a "strong-buy" rating in a report on Tuesday, July 21st.

Equillium Price Performance

Shares of EQ stock opened at $1.68 on Tuesday. The business's fifty day moving average price is $2.21 and its 200 day moving average price is $2.34. The firm has a market capitalization of $106.53 million, a PE ratio of -8.40 and a beta of 1.81. Equillium has a 1-year low of $0.76 and a 1-year high of $3.54.

Equillium (NASDAQ:EQ - Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.01. Equities research analysts expect that Equillium will post -0.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Equillium

A number of large investors have recently bought and sold shares of the stock. Janus Henderson Group PLC raised its holdings in shares of Equillium by 10.8% in the first quarter. Janus Henderson Group PLC now owns 6,494,571 shares of the company's stock worth $12,957,000 after acquiring an additional 632,359 shares during the last quarter. Jupiter Topco LLC acquired a new position in Equillium in the 2nd quarter valued at about $20,685,000. ADAR1 Capital Management LLC purchased a new position in Equillium in the 2nd quarter valued at about $12,027,000. Eversept Partners LP acquired a new stake in shares of Equillium during the 1st quarter worth about $2,998,000. Finally, Affinity Asset Advisors LLC acquired a new stake in shares of Equillium during the 1st quarter worth about $2,453,000. Institutional investors and hedge funds own 27.05% of the company's stock.

Equillium Company Profile

Equillium, Inc is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company's research is based on modulating immune pathways involved in T-cell activation, inflammation and tissue damage.

Its lead investigational product is itolizumab, an anti-CD6 monoclonal antibody designed to regulate pathogenic T-cell activity. Equillium has evaluated itolizumab in immune-mediated conditions, including acute graft-versus-host disease and other inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.